Home > Browse Research > Life Sciences > Pharmaceuticals > Research & Development

Research & Development: market research reports

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce.

In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

Research & Development market research reports and industry analysis

The World Market for Pain Management Drugs and Devices 5/20/2013 \| published by: Kalorama Information ... as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the ... \| read more...	$3,500.00
China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi 5/20/2013 \| published by: Access China Management Consulting Ltd. ... a precise chemical structural formula, but also the indications of the majority of traditional Chinese medicines still can not been clearly described by the modern medical terminologies. How the Chinese drug authorities to administer the ... \| read more...	$750.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players 5/15/2013 \| published by: GlobalData ... up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the ... \| read more...	$2,995.00
China Pharmaceutical Guidebook Series (3) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products 5/10/2013 \| published by: Access China Management Consulting Ltd. ... behind the developed countries. The requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and harmonized. In China, the pharmaceutical regulatory authority ----- ... \| read more...	$750.00
Hypertension Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Anti-Obesity Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ... \| read more...	$2,000.00
Osteoporosis Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Anti-Tumor Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ... \| read more...	$2,000.00
Global Markets for Infectious Disease Treatments 5/1/2013 \| published by: BCC Research ... data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017 Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans Examination of technological developments, future trends, ... \| read more...	$5,450.00
Blood Disease Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ... \| read more...	$2,000.00
Mental Illness Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ... \| read more...	$2,000.00
Lymphoma Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry 4/30/2013 \| published by: GlobalData ... the Pharmaceutical Industry report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 ... \| read more...	$2,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or ... \| read more...	$4,995.00
Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. ... \| read more...	$3,495.00
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players 4/29/2013 \| published by: GBI Research ... latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, ... \| read more...	$3,500.00
Scientific Research & Development in the US - Industry Risk Rating Report 4/24/2013 \| published by: IBISWorld ... or otherwise, of the business operating environment'. The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry ... \| read more...	$1,020.00
Angiogenesis in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... number of ceased drugs over the last years amount to another 142 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >